---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006260"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-10-03T23:59:59+00:00"
generated_at: "2026-05-17T04:41:57.533521+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience gets 180-day Nasdaq bid-price extension, transfers to Capital Market

## Summary
- Nasdaq granted until March 30, 2026 to reach $1.00 minimum bid price for 10 consecutive days.
- Common stock transferred from Nasdaq Global Market to Capital Market effective October 3, 2025; ticker HBIO remains.
- Company previously disclosed deficiency in April 2025 when bid price fell below $1.00 for 30 consecutive days.
- If compliance not met by March 30, 2026, delisting proceedings may begin; Company may consider a reverse stock split.
- No assurance of regaining compliance; Company will monitor closing bid price and evaluate options.

## SEC filing metadata
- accession: 0001171843-25-006260
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-10-03T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325006260/0001171843-25-006260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325006260/f8k_100225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006260
- JSON: https://secwatch.observer/filing/0001171843-25-006260.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006260.txt

## Source-grounded claims
- claim_id: c097b03b67aca8a752df9236e27d7d1936bc442e
  claim: HARVARD BIOSCIENCE INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: October 2, 2025, Harvard Bioscience, Inc., (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until March 30, 2026 (the “Second Compliance Period”), to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184325006260/0001171843-25-006260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.